Articles related to SICKLE CELL DISEASE (SCD)

The FDA’s recent decision allows Fulcrum Therapeutics to continue its Phase 1b trial of FTX-6058, an oral therapy for SCD. The trial aims to explore the drug’s potential in increasing fetal hemoglobin levels, offering a new avenue for treatment.

Home-based therapies are emerging as a viable solution to the challenges faced by global healthcare systems, particularly for conditions like sickle cell disease. Dive deeper into the research and implications for patient care.

Explore the impacts of sickle cell disease on ocular health through an insightful case study of an 11-year-old patient. Uncover the significance of vigilant monitoring, the promise of spontaneous regression, and the crucial role of various diagnostic tools in managing sickle cell retinopathy.

Treading the line between cost-effectiveness and equity in SCD management, gene therapy presents a paradigm shift. Curious about the economic equilibrium in this new era of treatment? Dive into the latest research insights.

The FDA announced a trial hold after two participants with sickle cell disease (SCD) in the LentiGlobin gene therapy trials developed AML and MDS. According to bluebird bio, the manufacturer of LentiGlobin products, the company was unable to find any cancer cells in the patient’s bone marrow and has asked the FDA for permission to resume clinical trials.